National Pension Service Purchases 3,887 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

National Pension Service raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 186,310 shares of the biopharmaceutical company’s stock after purchasing an additional 3,887 shares during the quarter. National Pension Service’s holdings in Regeneron Pharmaceuticals were worth $163,634,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Meyer Handelman Co. boosted its position in Regeneron Pharmaceuticals by 11.4% during the 3rd quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after buying an additional 435 shares during the period. Stifel Financial Corp grew its stake in shares of Regeneron Pharmaceuticals by 12.2% in the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after purchasing an additional 3,385 shares during the last quarter. LPL Financial LLC increased its holdings in Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after purchasing an additional 3,479 shares during the period. Exchange Traded Concepts LLC raised its position in Regeneron Pharmaceuticals by 32.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after purchasing an additional 1,221 shares during the last quarter. Finally, Monetary Management Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 4.8% during the 3rd quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock worth $901,000 after buying an additional 50 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.5 %

Shares of Regeneron Pharmaceuticals stock traded down $14.21 during trading hours on Wednesday, reaching $955.76. The company’s stock had a trading volume of 390,075 shares, compared to its average volume of 495,489. The company has a market capitalization of $104.91 billion, a P/E ratio of 28.24, a P/E/G ratio of 2.74 and a beta of 0.17. The stock’s fifty day simple moving average is $942.67 and its two-hundred day simple moving average is $899.44. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Bank of America raised their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a report on Friday, April 12th. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Morgan Stanley upped their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $981.71.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Joseph J. Larosa sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $967.65, for a total value of $967,650.00. Following the completion of the transaction, the executive vice president now owns 37,543 shares in the company, valued at approximately $36,328,483.95. The disclosure for this sale can be found here. Insiders have sold 8,095 shares of company stock worth $7,779,766 in the last quarter. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.